Irsenontrine clinical trials
Also written E2027.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses irsenontrine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses irsenontrine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid CopathologyCompletedPhase 2Eisai Inc.NCT04764669Written as E2027
- Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy BodiesCompletedPhase 2Eisai Inc.NCT03467152Written as Irsenontrine
- A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male ParticipantsCompletedPhase 1Eisai Inc.NCT04023877Written as E2027
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy SubjectsCompletedPhase 1Eisai Inc.NCT02873156Written as E2027
- Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult SubjectsCompletedPhase 1Eisai Inc.NCT02415790Written as E2027
- Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy SubjectsCompletedPhase 1Eisai Co., Ltd.NCT02947711Written as E2027
Codes
What other systems call irsenontrine · ClinicalTrials.gg INT014998
- UNII (FDA) 54QB00NNRBIRSENONTRINEOne source FDA
- NCI Thesaurus C179092IrsenontrineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 54QB00NNRB | IRSENONTRINE | One source FDA |
| NCI Thesaurus | C179092 | Irsenontrine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.